Core Viewpoint - The company, Tonghua Golden Horse, has announced a resolution from its 11th Board of Directors meeting to apply for a loan from the bank using its own assets as collateral, indicating a strategic move to secure financing for operational needs [1] Group 1: Loan Application Details - The company plans to apply for a financing loan not exceeding 120 million yuan, which is intended to be used in a revolving manner within the specified period [1] - The loan application is in response to an upcoming maturity of a loan previously applied to the Bank of China, Tonghua Branch, in 2025 [1] Group 2: Collateral Information - The financing will be secured by part of the company's own land and properties, with a total book value of 194.9281 million yuan as of September 30, 2025 [1] - The collateral represents 4.24% of the company's most recent audited total assets, indicating a relatively low leverage ratio [1] Group 3: Voting Outcome - The resolution to approve the loan application received unanimous support, with 9 votes in favor, 0 against, and 0 abstentions [1]

Core Viewpoint - Tonghua Jinma's stock price has shown significant growth this year, with an increase of 82.23% year-to-date, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million yuan, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.96 million yuan, reflecting a year-on-year increase of 4.35% [2]. - The company has cumulatively distributed 210 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of December 22, the stock price was 28.61 yuan per share, with a market capitalization of 27.651 billion yuan. The stock experienced a trading volume of 334 million yuan and a turnover rate of 1.23% [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent appearance on September 11, where it recorded a net buy of 142 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders was 38,200, a decrease of 3.20% from the previous period, with an average of 25,266 shares held per shareholder, an increase of 3.31% [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with varying changes in their holdings compared to the previous period [3].

Core Viewpoint - Tonghua Golden Horse is actively preparing for the commercialization of its innovative drug, Huopo Batyhyl Amino Acids Tablets, which is currently undergoing final review by the National Medical Products Administration (NMPA) [1][2] Group 1: Company Overview - Tonghua Golden Horse primarily engages in the research, production, and sales of pharmaceutical products, with business units including Shengtai Biological, Yongkang Pharmaceutical, and Yuanshou Biological [1] - The company's product range covers various therapeutic areas such as oncology, microbiology, cardiovascular, detoxification, digestive system, musculoskeletal system, gynecology, and neurology [1] Group 2: Drug Development Progress - The Huopo Batyhyl Amino Acids Tablets, a national-level new drug with independent intellectual property rights, has completed all necessary clinical trials and is awaiting final review by the Center for Drug Evaluation (CDE) [2] - The company has submitted all required technical documents and completed expert review meetings in clinical, statistical, and pharmaceutical aspects as part of the new drug application process [2] Group 3: Commercialization Strategy - Tonghua Golden Horse has established a professional team and innovative marketing model to ensure control over the sales of the new drug, balancing profit margins with patient accessibility [2] - The existing production system is prepared to meet the demand for Alzheimer's disease treatment, ensuring rapid market entry post-approval [2] - The company is focusing on expanding its pipeline in the field of neurological diseases, aiming to create a robust research and development structure [2][3]

Group 1: Regulatory Progress - The Acarbose project has completed all professional reviews and is currently undergoing final comprehensive evaluation, with all necessary technical materials submitted as per CDE requirements [2] - The company has completed all tasks related to the new drug application and is awaiting the final review from CDE [2] Group 2: Innovation and Pipeline Strategy - The company has seen a gradual increase in available funds, enabling ongoing internal research and external collaborations to enrich the existing pipeline [2] - Future pipeline strategies will prioritize deepening focus in the neurological disease field, establishing a healthy research and development hierarchy of "one batch on the market, one batch in clinical trials, and one batch in pre-research" [2] Group 3: Commercialization Preparation - The company has completed full-process preparations for the commercialization of the new drug, including the establishment of a professional team and innovative marketing models [3] - The existing production system is adequately prepared to meet the medication needs of Alzheimer's patients, ensuring rapid market entry post-approval [3]

Group 1 - The company, Tonghua Golden Horse, has completed the professional review work for its new chemical drug, Amber Dihydroaminoacridine Tablets, and has entered the comprehensive review stage [2] - The company assures that all review processes are proceeding normally and will disclose significant information regarding the new drug through designated media [2]

从通化金马十大流通股东角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 数据显示，南方基金旗下1只基金位居通化金马十大流通股东。南方中证1000ETF（512100）三季度减 持9.23万股，持有股数884.16万股，占流通股的比例为0.92%。根据测算，今日浮盈赚取约1220.14万 元。 责任编辑：小浪快报 12月2日，通化金马涨5.02%，截至发稿，报28.85元/股，成交3.44亿元，换手率1.27%，总市值278.83亿 元。 截至发稿，崔蕾累计任职时间7年27天，现任基金资产总规模1227.6亿元，任职期间最佳基金回报 172.91%， 任职期间最差基金回报-15.93%。 资料显示，通化金马药业集团股份有限公司位于吉林省通化市二道江区金马路999号，成立日期1993年2 月26日，上市日期1997年4月30日，公司主营业务涉及药品的研发、生产和销售。主营业务收入构成 为：生化药59.27%，中成药40.56%，原料药0.10%，其他0.07%。 南方中证 ...

吉林秉责律师事务所 关于通化金马药业集团股份有限公司 2025 年第四次临时股东会的法律意见书 致：通化金马药业集团股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国 公司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会 规则》"）和《通化金马药业集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，吉林秉责律师事务所（以下简称"本所"）接受了通化金马药业集 团股份有限公司（以下简称"公司"）的委托，担任公司 2025 年第四次临时股东 会（以下简称"本次股东会"）特聘专项法律顾问并出具法律意见书。 本法律意见书仅供公司为本次股东会之目的而使用，不得用于其他任何目的。 本所同意公司将本法律意见书作为本次股东会的公告材料，随其他需要公告的信 息一起向公众披露，并依法对本所在其中发表的法律意见承担责任。 为出具本法律意见书，本所指派郭淑芬、裴昕桐律师出席了公司于 2025 年 11 月 28 日下午 14 点 30 分在公司七楼会议室召开的本次股东会，审查了公司提 供的召开本次股东会有关的文件和资料，并进行了验证。在此基础上，本所按照 律师行 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-45 通化金马药业集团股份有限公司 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会无否决提案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、召开时间： 现场会议召开时间为：2025年11月28日下午14:30 网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年11月28日9:15—9:25，9:30—11:30和13:00—15:00；通过互联网投票系 统进行网络投票的具体时间为2025年11月28日上午9:15至下午15:00期间的任意 时间。 2、召开地点：吉林省通化市二道江区金马路999号，公司七楼会议室。 3、召开方式：采用现场表决与网络投票相结合的方式召开 4、召集人：公司董事会 5、现场会议主持人：董事长张玉富先生 6、会议召开的合法、合规性：本次会议的召集、召开与表决程序符合《公 司法》《上市公司股东会规则》《深圳证券交易所股票上市规则》等有关法律、行 ...

Core Viewpoint - Tonghua Golden Horse (000766) has announced that its chemical Class 1 new drug, Amber Dihydroaminoacridine Tablets, has completed all professional review work and has entered the comprehensive review stage, with all review processes proceeding normally [1] Group 1 - The company has responded to investor inquiries on November 26 regarding the progress of its new drug [1] - The company emphasizes that any significant information regarding the new drug will be disclosed through designated information disclosure media, urging investors to pay attention to company announcements [1]

Core Viewpoint - Tonghua Jinma's stock price has shown significant volatility, with a year-to-date increase of 76.31%, but a recent decline of 3.72% over the last five trading days [1] Group 1: Stock Performance - As of November 26, Tonghua Jinma's stock price was 27.68 CNY per share, with a market capitalization of 26.753 billion CNY [1] - The stock has experienced a trading volume of 73.0787 million CNY, with a turnover rate of 0.28% [1] - The company has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) twice this year, with the latest appearance on September 11, where it recorded a net buy of 142 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million CNY, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.9635 million CNY, an increase of 4.35% [2] - The company's main business revenue composition includes biopharmaceuticals (59.27%), traditional Chinese medicine (40.56%), raw materials (0.10%), and others (0.07%) [1] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tonghua Jinma was 38,200, a decrease of 3.20% from the previous period [2] - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with varying changes in their holdings [3]